SOURCE: MMRGlobal, Inc.

MMRGlobal, Inc.

February 08, 2012 08:35 ET

MMRGlobal Goes Into 2012 Highlighting $43 Million in Projected Revenues From Existing Signed Agreements

LOS ANGELES, CA--(Marketwire - Feb 8, 2012) - MMRGlobal, Inc. (OTCBB: MMRF) ("MMR"), a leading provider of Personal Health Records ("PHR"), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced that going into the upcoming HIMSS Conference and Exhibition, February 20-24, in Las Vegas (, it has entered into agreements for more than $43 million based on licensing and strategic partnerships pertaining to the Company's biotech and health information technology intellectual property, all of which are specifically described in, and or attached to, MMRGlobal's filings with the Securities and Exchange Commission.

Since the Company's inception, it has invested more than $152 million on biotech and health IT-related Research and Development projects and currently has more than 40 patents issued, pending and or applied for worldwide, including patents pertaining to the Company's FavId®/Specifid™ vaccine trials and anti-CD20 antibody assets, the second widely believed to be a first cousin to Rituximab. Additionally, MMR's Method and System for Providing Online Medical Records patents were recently valued in a range from $300 million to as much as $800 million ( The Company also owns other biotech assets including thousands of patient tumor samples believed to be worth additional millions.

"Although the Company's primary business remains the offering of its Personal Health Record and MMRPro professional document imaging and scanning solutions, the value of our intellectual property is growing," said Robert H. Lorsch, MMRGlobal Chairman and CEO. "Clearly, as we move into the future, we will seek opportunities to leverage our intellectual property and enter into agreements with strategic partners in patient care and other similar lines of business as well as with companies that specialize in maximizing the value of IP, such as Acacia Research or RPX Corporation and others who have successfully leveraged the values of intellectual property into billions of dollars of valuation for shareholders."

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId®/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. and its products, visit

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, whether or not such statement relates directly to the Company's future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, licensing, defending, protecting and maximizing the value of our biotechnology and health information technology intellectual property; the risk the Company's products are not adopted or viewed favorably by the healthcare community; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information